Miniaturized screening technologies for drug discovery

被引：3

作者：

Cooper, JM ^{[1
]}

Cass, AEG

机构：

[1] Univ Glasgow, Dept Elect, Glasgow G12 8LT, Lanark, Scotland

[2] Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England

来源：

BIOCHEMICAL SOCIETY TRANSACTIONS | 2002年 / 30卷

关键词：

cell screen; high throughput; proteomics;

D O I：

10.1042/bst0300802

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Adaptive Profiling (APL) and other biochip companies aim to harness the power of microsystems technology together with advances in chemistry and molecular biology, to become service and technology providers to organizations involved in pharmaceutical research and development. By supplying a unique range of decision-making tools that aid an earlier identification of qualified drug candidates for clinical development, the company should gain a significant share of the US$10 billion biological screening, bioavailability and toxicity assessment market.

引用

页码：802 / 806

页数：5